CA1272972A - Vector encoding hepatitis b surface antigen - Google Patents
Vector encoding hepatitis b surface antigenInfo
- Publication number
- CA1272972A CA1272972A CA000476721A CA476721A CA1272972A CA 1272972 A CA1272972 A CA 1272972A CA 000476721 A CA000476721 A CA 000476721A CA 476721 A CA476721 A CA 476721A CA 1272972 A CA1272972 A CA 1272972A
- Authority
- CA
- Canada
- Prior art keywords
- vector
- surface antigen
- hepatitis
- cell
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Abstract
Abstract of the Disclosure Recombinant DNA vector including (1) a promoter for a eukaryotic metallothionein gene ligated to a gene sequence encoding hepatitis B surface antigen, and (2) at least the 69% transforming region of the bovine papilloma genome, expression of the hepatitis B surface antigen encoding gene sequence being under the control of the metallothionein promoter.
Description
r _~ Back~round of the Invention - This invention relates to the use of recombinant DNA techniques to produce hepatitis B
surface antigen (HBsAg).
Hepatitis B virus (HBV) is the infectious agent of serum hepatitis. Infection by this virus is a worldwide health problem; carriers of HBV can suffer from transient or chronic infection, the latter having the potential of progressing to liver cancer. The HBV
infectious agent has been identified as the 42 nm Dane ,~,, ~ particle which contains a lipoprotein coat of hepatitis surface antigen surrounding an internal core particle consisting of a DNA polymerse and the 3200 base pair (bp) DNA genome. HBsAg is found in the serum of HBV
carriers mainly in the form of 22 nm spherical particles ~ or ~ilaments and is observed to be the major target for - the HBV neutralizing antibody. The 22 nm particles ~~ contain two polypeptides of apparent molecular weights a of 22,000 and 27,000 daltons. These polypeptides are 20 prooably identical, differing only in the presence of glycosylation in the larger peptide. Because of the clinical importance of developing vaccines against HBsAg, a major effort has been undertaken by a number of laboratories to isolate HBsAg protein.
The HBV gene has been cloned into Escherischia <~ coli and the complete nucleotide sequence has been determined, e.g., by Burrel et al. (1979) Nature ~79, 43. The HBV DNA is a partially double stranded molecule with a single-stranded gap in one strand (L) and DNA of 3 variable length in the second strana. The HBsAg gene has been cloned in Escherischia coli and has been shown to contain an open reading frame of 680bp with no intervening sequences. A variety of systems have been . employed in order to transfer the HBsAg DNA sequences .'fv`~
.,.~ .
~j ,.~
~D
, ....
;~
'' , ''-': ' ' -- ;; :
:~
:: .
into a host cell and obtain expression of H~sAg. Varying levels of HBsAg expression have been detected in yeast and mammalian cells transformed with viral vectors such as SV40 and retroviruses. For example, Moriarty et al. 1981 Proc. Natl. Acad. Sci. 78 2606-2610 and Liu et al. 1982 DNA (1) 213-221 descri~e SV40 vectors that contain the HBsAg gene and are capable of transforming cultured mammalian cells.
Sarver et al (1981) Mol. and Cell. Biol. 1, 486-496;
DiMaio (1982~ P.N.A.S. USA 79, 4030-4034; and Zinn et al. (1982) 10 P.N.A.S. USA 79, 4897-4901 describe BPV vectors which express, respectively, rat preproinsulin, human beta-globin, and human beta-interferon when used to transform mammalian cells.
Summary of the Invention In general, the invention features a recombinant DNA
vector including (1) a promoter for a eukaryotic metallothionein gene ligated to a gene sequence encoding hepatitis B surface anti~
gen, and (2) at least the 69% transforming region of the bovine papilloma virus genome, expression of the hepatitis B
, ~ .
~ ":
...
.
; .... ~
- ~ ~2~72 surface antigen encoding gene sequence being under the control of the metallothionein promoter~
In preferred embodiments, mouse C127 cells transformed by the vector are capable of continuously (without passage) producing hepatitis B surface antigen for at least 60 days, most preferably at least 80 days;
the vector is capable of being maintained in transformed mouse Cl27 cells extrachromasomally in multiple copies;
; mouse C127 cells transformed with the vector are capable of producing hepatitis B surface antigen at a level of at least 5 mg/L(liter of culture medium)/24 hr, most -~ preferably at least 10 mg/L/24 hr, without induction by a heavy metal; production of hepatitis B surface antigen without induction by a heavy metal is at least as great as production of hepatitis B surface antigen by the same - system in the presence of cadmium; the vector includes ; all of the metaLlothionein gene; the metallothionein gene is a mouse metallothionein gene; and the host cell is a rodent fibroblast cell, most preferably a mouse C127 cell or an NIH 3T3 cell.
Mammalian cells transformed by the vector of -; the invention are capable of being cultured continuously for a long per~iod of time without passage or cell death;
.;~ the present system thus allows the continuous harvesting of HBsAg without the need for restarting the culture every time harvesting is carried out~ The continuous process thus makes collection of the antigen convenient ' ' ~ and reduces the frequency with which fresh cultures must :i~ be initiated. Furthermore, the plasmid of the invention -~ ~ 30 is maintained at high copy number in cultured cells, amplifying the HBsAg gene. HBsAg is expressed under ~ control of the MT promoter.
:
.: ~
:.:~:: ~ .:
~ -: . :
. : : :;
Levels of HBsAg production by transformed celllines of the invention are high, ranging from 5~g/L/24 hr to over I0 mg/L/24 hr.
High levels of HBsAg expression are obtained in transformed cells witho~t induction by cadmium or any other heavy metal, e.g., 2inc. Cell cultures can thus ~e prepared without the necessity of handling toxic _ substances, and purification of hepatitis B surface antigen is not complicated by the presence of toxic metals in the growth medium.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiment thereof, and from the claims.
Description of the Preferre~ Embodiment We now turn to a description of the preferred embodiment of the invention, after first briefly ~- describing the drawing.
~, Drawing ~-' The Figure is a diagrammatic representation of :~ 20 the construction of plasmids pRF300 and pRB-l.
': structllre The plasmid illustrated as plasmid pRB-l in the Figure contains a hybrid gene produced by the insertion of the HBsAg-encoding gene into the mouse MT gene between the MT promoter and the MT structural gene.
Plasmid pRB-l also contains the entire BPV genome, whlch causes the vector to transform mammalian cells.
Synthesis ,: --The vector of the invention is constructed using recombinant DNA techniques known in the art. A
:.
~ ~ .
..
~ ,~., :
~,;:
, ..
~,jj~, ~j ,- ~ ' ~,. . . :
c ~ r plasmid containing an MT gene and a lytic viral genome -is digested with an endonuclease restriction enzyme. A
gene encoding human HBsAg is then inserted within the MT
gene between the MT promoter and the MT structural gene. This intermeoiate plasmid, containing the - MT-HBsAg hybrid gene and the lytic viral genome, is digested to excise the lytic viral genome, which is then replaced by the BPV genome. The resulting plasmid contains the MT-HBsAg hybrid gene and the BPV genome.
Construction of pRB-l All plasmids are transformed into and maintained in E. coli strain MC 1061. Referring to the Figure, plasmid CL28 (referred to as PJYMMTC(E) in Hamer et al. (1983) J. Mol. Applied ~en. 1, 273), containing the mouse MT gene and the SV40 genome, is digested with Bgl II endonuclease restriction enzyme, opening the plasmid between the promoter region and the structural sequence of the MT gene. The 1.35 kb human HBsAg gene-containing Bam HI fragment Erom plasmid SuAM115 (a pBR-SV~0-HBsAg plasmid described in Moriarty et al.
; (1981) P.N.A.S. USA 78, 2605) is then cut out and : inserted at the Bgl II site of CL28 to form pRF300. The SV40 and some pBR se~uences in pRF300 are -then removed ~3 by Bam HI digestion; further digestion with Sal I enzyme yields a linear molecule with Bam HI and Sal I ends.
;~ Plasmid B2-2 (not shown), containing the entire - ~ BPV genome, is digested with Bam HI and Sal I enzymes ::` (Any source of the BPV genome can be used; BPV is -- available, for example, from New England Biolabs; B2-2 r'~ 30 was used here only because it has a convenient Sal I
site). The excised BPV-containing fragment, which also contains pBR DNA, i9 ligated to the HBsAg-MT hybrid gene-containing linear Bam HI-Sal I fragment. The .~ .
:
.~, ~. .
..~, . .
.
.
", , .,.
: , .. - .
; t ~z7~2i~
~ - 6 ;resulting plasmid, pRB-l, consists of the entire BPV
genome and the HBsAg structural gene inserted within the MT gene between the promoter and the remainder of the MT
gene.
Transformation of Mammalian Cells . . .
pRB~l plasmid DNA is introduced into mouse C127 cells ~sing a modification of the transfection technique of Wigler et al. (1977) Cell 11, 223, as follows.
5ug of pRB-l DNA is added to 0.5ml of a 240mM
~CaC12 solutinn containing lOug of carrier salmon sperm 10 DNAo This solution is bubbled into an equal volume of 2xHBS (280mM NaCl, 50mM Hepes, and 1.5mM sodium phosphate) having a pH of 7.1. The calcium phosphate is allowed to form for 30 minutes at room temperature, and 5x105 Cl27 cells are plated 24 hrs. prior to -15 transfection. While the calcium phosphate precipitate -: is rorming, the cell growtn medium is changed. The calcium phosphate precipitate is added to the cells and incubated for 6-8 hr~ at 37C. The DNA is removed and the cells are exposed to 20Yo glycerol in phosphate `~i20 buffered saline (PBS), pH 7, for 1-2 minutes at room :.
temperature. The cells are washed with PBS, and lOml of Dulbecco's modified medium with 10% fetal calf serum (MA
Biologicals), penicillin/streptomycin and lOmM glutamine (GIBCO) is added. The medium is changed 24 hrs. later and eve~y 3~4 days thereafter. Foci can be detected 'J`................ after 10 14 days and isolated by the cloning ring method after 21 days. The foci are expanded for analysis.
;;Mouse C127 cells tranformed with pRB-l were deposited in the American Type Culture Collection, Rockville, MD, and 3 given ATCC Accession No. CRL 8399.
Use Transformed cells are cultured using conventional techniques, and HBsAg is harvested .~
_ ..
;~ -~ ' .
:
. . : ~
. . .
. ~
~ 7 continuously from the cuLture medium, using conventional techniques, and is used to prepare hepatitis B vaccine, or for biochemical assays, also using well-known techni~ues.
HBsAg is secreted into the culture medium as 22 nm particles which can be observed in electromicrographs of the media.
pRB-l-transformed mouse C127 cells can exist for up to 85 days in confluent cell culture if the media is changed every 24-48 hr. The cells continually double, in the Elask or roller bottle, with growth cha~acteristics of transformed cells. We conclude that the combination of a strong metallothionein promoter controlllng HBsAg production in the BPV vector (whicn allows amplifie~ DNA copy number) and the continuous growth properties of the BPV transformed cells provide an optimal system for scale up production of the HBsAg.
Other Embod1ments Other embodiments are within the following claims. For example, although the use of all of the BPV
; genome is preferred, just the 69% transforming region can also be used. However, when only the 69~ region is used, the~é can be undesirable interactions between the plasmid and the chromosome of the host cell, i.e., much of the plasmid DNA can incorporate into the chromosone rather than remaining episomal, so that the plasmid is :~. very difficult to retrieve from the cells. Also, if . ~,;
^` less than the entire BPV genome is used, the pBR region which is frequently attached to BPV (since BPV is normally provided as part of a pBR322-derived plasmid~, ; must be cut out prior t~ transfection, because the pBR
region, in a less than complete BPV fragment, can have an inhibitory effect on transfection, while this does not occur when using all of BPV. Undersirable . ~
. .~
. -:
.:, ~r".,~ .
__ .
;.. ~ -'~
' ' . .~ '' ' ' :~ . ' ': .~ .
. . - .
-:
~ r ~2~7297~
.
rearrangements can also occur when using only the 69~ -region~
It is preferable that the eukaryotic metallothionein promoter be of mammalian, most - 5 preferably murine, origin, but any suitable metallothionein prornoter can be used (each mammalian species which produces a metallothionein apparently does so using a structurally different gene).
To construct a vector within the invention, other than pRB-1, cell line DNA can be used as the ,; source of the MT promoter and structural gene, the HBsAg gene, and the BPV genome, and those genetic elements can be inserted, using conventional recombinant DNA
techniques, into a desired vector.
Any suitable host cells can be used~ For example, other rodent fibroblast cell lines which can be ;. infected ~y BPV can be used; for example, NIr~ 3~13 cells (AT~C CCL 92) can be used.
' .
, ':
~, ~ .
,,..,,., ;, ., : ~
. .
.. ..
,~
, . :
. . .~", , .. ..
:.-, .:j , .
r~
.~, :: -:~ .. ' .
~` ~
:~, ~ . ::
....
surface antigen (HBsAg).
Hepatitis B virus (HBV) is the infectious agent of serum hepatitis. Infection by this virus is a worldwide health problem; carriers of HBV can suffer from transient or chronic infection, the latter having the potential of progressing to liver cancer. The HBV
infectious agent has been identified as the 42 nm Dane ,~,, ~ particle which contains a lipoprotein coat of hepatitis surface antigen surrounding an internal core particle consisting of a DNA polymerse and the 3200 base pair (bp) DNA genome. HBsAg is found in the serum of HBV
carriers mainly in the form of 22 nm spherical particles ~ or ~ilaments and is observed to be the major target for - the HBV neutralizing antibody. The 22 nm particles ~~ contain two polypeptides of apparent molecular weights a of 22,000 and 27,000 daltons. These polypeptides are 20 prooably identical, differing only in the presence of glycosylation in the larger peptide. Because of the clinical importance of developing vaccines against HBsAg, a major effort has been undertaken by a number of laboratories to isolate HBsAg protein.
The HBV gene has been cloned into Escherischia <~ coli and the complete nucleotide sequence has been determined, e.g., by Burrel et al. (1979) Nature ~79, 43. The HBV DNA is a partially double stranded molecule with a single-stranded gap in one strand (L) and DNA of 3 variable length in the second strana. The HBsAg gene has been cloned in Escherischia coli and has been shown to contain an open reading frame of 680bp with no intervening sequences. A variety of systems have been . employed in order to transfer the HBsAg DNA sequences .'fv`~
.,.~ .
~j ,.~
~D
, ....
;~
'' , ''-': ' ' -- ;; :
:~
:: .
into a host cell and obtain expression of H~sAg. Varying levels of HBsAg expression have been detected in yeast and mammalian cells transformed with viral vectors such as SV40 and retroviruses. For example, Moriarty et al. 1981 Proc. Natl. Acad. Sci. 78 2606-2610 and Liu et al. 1982 DNA (1) 213-221 descri~e SV40 vectors that contain the HBsAg gene and are capable of transforming cultured mammalian cells.
Sarver et al (1981) Mol. and Cell. Biol. 1, 486-496;
DiMaio (1982~ P.N.A.S. USA 79, 4030-4034; and Zinn et al. (1982) 10 P.N.A.S. USA 79, 4897-4901 describe BPV vectors which express, respectively, rat preproinsulin, human beta-globin, and human beta-interferon when used to transform mammalian cells.
Summary of the Invention In general, the invention features a recombinant DNA
vector including (1) a promoter for a eukaryotic metallothionein gene ligated to a gene sequence encoding hepatitis B surface anti~
gen, and (2) at least the 69% transforming region of the bovine papilloma virus genome, expression of the hepatitis B
, ~ .
~ ":
...
.
; .... ~
- ~ ~2~72 surface antigen encoding gene sequence being under the control of the metallothionein promoter~
In preferred embodiments, mouse C127 cells transformed by the vector are capable of continuously (without passage) producing hepatitis B surface antigen for at least 60 days, most preferably at least 80 days;
the vector is capable of being maintained in transformed mouse Cl27 cells extrachromasomally in multiple copies;
; mouse C127 cells transformed with the vector are capable of producing hepatitis B surface antigen at a level of at least 5 mg/L(liter of culture medium)/24 hr, most -~ preferably at least 10 mg/L/24 hr, without induction by a heavy metal; production of hepatitis B surface antigen without induction by a heavy metal is at least as great as production of hepatitis B surface antigen by the same - system in the presence of cadmium; the vector includes ; all of the metaLlothionein gene; the metallothionein gene is a mouse metallothionein gene; and the host cell is a rodent fibroblast cell, most preferably a mouse C127 cell or an NIH 3T3 cell.
Mammalian cells transformed by the vector of -; the invention are capable of being cultured continuously for a long per~iod of time without passage or cell death;
.;~ the present system thus allows the continuous harvesting of HBsAg without the need for restarting the culture every time harvesting is carried out~ The continuous process thus makes collection of the antigen convenient ' ' ~ and reduces the frequency with which fresh cultures must :i~ be initiated. Furthermore, the plasmid of the invention -~ ~ 30 is maintained at high copy number in cultured cells, amplifying the HBsAg gene. HBsAg is expressed under ~ control of the MT promoter.
:
.: ~
:.:~:: ~ .:
~ -: . :
. : : :;
Levels of HBsAg production by transformed celllines of the invention are high, ranging from 5~g/L/24 hr to over I0 mg/L/24 hr.
High levels of HBsAg expression are obtained in transformed cells witho~t induction by cadmium or any other heavy metal, e.g., 2inc. Cell cultures can thus ~e prepared without the necessity of handling toxic _ substances, and purification of hepatitis B surface antigen is not complicated by the presence of toxic metals in the growth medium.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiment thereof, and from the claims.
Description of the Preferre~ Embodiment We now turn to a description of the preferred embodiment of the invention, after first briefly ~- describing the drawing.
~, Drawing ~-' The Figure is a diagrammatic representation of :~ 20 the construction of plasmids pRF300 and pRB-l.
': structllre The plasmid illustrated as plasmid pRB-l in the Figure contains a hybrid gene produced by the insertion of the HBsAg-encoding gene into the mouse MT gene between the MT promoter and the MT structural gene.
Plasmid pRB-l also contains the entire BPV genome, whlch causes the vector to transform mammalian cells.
Synthesis ,: --The vector of the invention is constructed using recombinant DNA techniques known in the art. A
:.
~ ~ .
..
~ ,~., :
~,;:
, ..
~,jj~, ~j ,- ~ ' ~,. . . :
c ~ r plasmid containing an MT gene and a lytic viral genome -is digested with an endonuclease restriction enzyme. A
gene encoding human HBsAg is then inserted within the MT
gene between the MT promoter and the MT structural gene. This intermeoiate plasmid, containing the - MT-HBsAg hybrid gene and the lytic viral genome, is digested to excise the lytic viral genome, which is then replaced by the BPV genome. The resulting plasmid contains the MT-HBsAg hybrid gene and the BPV genome.
Construction of pRB-l All plasmids are transformed into and maintained in E. coli strain MC 1061. Referring to the Figure, plasmid CL28 (referred to as PJYMMTC(E) in Hamer et al. (1983) J. Mol. Applied ~en. 1, 273), containing the mouse MT gene and the SV40 genome, is digested with Bgl II endonuclease restriction enzyme, opening the plasmid between the promoter region and the structural sequence of the MT gene. The 1.35 kb human HBsAg gene-containing Bam HI fragment Erom plasmid SuAM115 (a pBR-SV~0-HBsAg plasmid described in Moriarty et al.
; (1981) P.N.A.S. USA 78, 2605) is then cut out and : inserted at the Bgl II site of CL28 to form pRF300. The SV40 and some pBR se~uences in pRF300 are -then removed ~3 by Bam HI digestion; further digestion with Sal I enzyme yields a linear molecule with Bam HI and Sal I ends.
;~ Plasmid B2-2 (not shown), containing the entire - ~ BPV genome, is digested with Bam HI and Sal I enzymes ::` (Any source of the BPV genome can be used; BPV is -- available, for example, from New England Biolabs; B2-2 r'~ 30 was used here only because it has a convenient Sal I
site). The excised BPV-containing fragment, which also contains pBR DNA, i9 ligated to the HBsAg-MT hybrid gene-containing linear Bam HI-Sal I fragment. The .~ .
:
.~, ~. .
..~, . .
.
.
", , .,.
: , .. - .
; t ~z7~2i~
~ - 6 ;resulting plasmid, pRB-l, consists of the entire BPV
genome and the HBsAg structural gene inserted within the MT gene between the promoter and the remainder of the MT
gene.
Transformation of Mammalian Cells . . .
pRB~l plasmid DNA is introduced into mouse C127 cells ~sing a modification of the transfection technique of Wigler et al. (1977) Cell 11, 223, as follows.
5ug of pRB-l DNA is added to 0.5ml of a 240mM
~CaC12 solutinn containing lOug of carrier salmon sperm 10 DNAo This solution is bubbled into an equal volume of 2xHBS (280mM NaCl, 50mM Hepes, and 1.5mM sodium phosphate) having a pH of 7.1. The calcium phosphate is allowed to form for 30 minutes at room temperature, and 5x105 Cl27 cells are plated 24 hrs. prior to -15 transfection. While the calcium phosphate precipitate -: is rorming, the cell growtn medium is changed. The calcium phosphate precipitate is added to the cells and incubated for 6-8 hr~ at 37C. The DNA is removed and the cells are exposed to 20Yo glycerol in phosphate `~i20 buffered saline (PBS), pH 7, for 1-2 minutes at room :.
temperature. The cells are washed with PBS, and lOml of Dulbecco's modified medium with 10% fetal calf serum (MA
Biologicals), penicillin/streptomycin and lOmM glutamine (GIBCO) is added. The medium is changed 24 hrs. later and eve~y 3~4 days thereafter. Foci can be detected 'J`................ after 10 14 days and isolated by the cloning ring method after 21 days. The foci are expanded for analysis.
;;Mouse C127 cells tranformed with pRB-l were deposited in the American Type Culture Collection, Rockville, MD, and 3 given ATCC Accession No. CRL 8399.
Use Transformed cells are cultured using conventional techniques, and HBsAg is harvested .~
_ ..
;~ -~ ' .
:
. . : ~
. . .
. ~
~ 7 continuously from the cuLture medium, using conventional techniques, and is used to prepare hepatitis B vaccine, or for biochemical assays, also using well-known techni~ues.
HBsAg is secreted into the culture medium as 22 nm particles which can be observed in electromicrographs of the media.
pRB-l-transformed mouse C127 cells can exist for up to 85 days in confluent cell culture if the media is changed every 24-48 hr. The cells continually double, in the Elask or roller bottle, with growth cha~acteristics of transformed cells. We conclude that the combination of a strong metallothionein promoter controlllng HBsAg production in the BPV vector (whicn allows amplifie~ DNA copy number) and the continuous growth properties of the BPV transformed cells provide an optimal system for scale up production of the HBsAg.
Other Embod1ments Other embodiments are within the following claims. For example, although the use of all of the BPV
; genome is preferred, just the 69% transforming region can also be used. However, when only the 69~ region is used, the~é can be undesirable interactions between the plasmid and the chromosome of the host cell, i.e., much of the plasmid DNA can incorporate into the chromosone rather than remaining episomal, so that the plasmid is :~. very difficult to retrieve from the cells. Also, if . ~,;
^` less than the entire BPV genome is used, the pBR region which is frequently attached to BPV (since BPV is normally provided as part of a pBR322-derived plasmid~, ; must be cut out prior t~ transfection, because the pBR
region, in a less than complete BPV fragment, can have an inhibitory effect on transfection, while this does not occur when using all of BPV. Undersirable . ~
. .~
. -:
.:, ~r".,~ .
__ .
;.. ~ -'~
' ' . .~ '' ' ' :~ . ' ': .~ .
. . - .
-:
~ r ~2~7297~
.
rearrangements can also occur when using only the 69~ -region~
It is preferable that the eukaryotic metallothionein promoter be of mammalian, most - 5 preferably murine, origin, but any suitable metallothionein prornoter can be used (each mammalian species which produces a metallothionein apparently does so using a structurally different gene).
To construct a vector within the invention, other than pRB-1, cell line DNA can be used as the ,; source of the MT promoter and structural gene, the HBsAg gene, and the BPV genome, and those genetic elements can be inserted, using conventional recombinant DNA
techniques, into a desired vector.
Any suitable host cells can be used~ For example, other rodent fibroblast cell lines which can be ;. infected ~y BPV can be used; for example, NIr~ 3~13 cells (AT~C CCL 92) can be used.
' .
, ':
~, ~ .
,,..,,., ;, ., : ~
. .
.. ..
,~
, . :
. . .~", , .. ..
:.-, .:j , .
r~
.~, :: -:~ .. ' .
~` ~
:~, ~ . ::
....
Claims (19)
1. A recombinant DNA vector comprising (1) a promoter for a eukaryotic metallothionein gene ligated to a gene sequence encoding human hepatitis B surface antigen, and (2) at least the 69% transforming region of the bovine papilloma virus genome, expression of said hepatitis B surface antigen encoding gene sequence being under the control of said metallothionein promoter.
2. The vector of claim 1 wherein mouse C127 cells transformed by said vector are capable of continuously producing said hepatitis B surface antigen for at least 60 days.
3. The vector of claim 1 wherein mouse C127 cells transformed by said vector are capable of producing said hepatitis B surface antigen at a level of at least 5mg/L/24 hr.
4. The vector of claim 1 wherein mouse C127 cells transformed by said vector are capable of producing said hepatitis B surface antigen without induction by a heavy metal.
5. The vector of claim 1 wherein said vector comprises all of said bovine papilloma virus genome.
6. The vector of claim 1, said vector being capable of being maintained in transformed mouse C127 cells extrachromasomally in multiple copies.
7. The vector of claim 2, said cells being capable of the continuous production of hepatitis B
surface antigen for at least 80 days.
surface antigen for at least 80 days.
3. The vector of claim 4 wherein mouse C127 cells transformed by said vector are capable of producing hepatitis B surface antigen at a level of at least 5mg/L/24 hrs without induction by a heavy metal.
9. The vector of claim 8 wherein said cells are capable of producing heptiatis B surface antigen at a level of at least 10mg/L/24 hr without induction by a heavy metal.
10. The vector of claim 4, said cells being capable of producing hepatitis B surface antigen, without induction by a heavy metal, at a level as high as the production of hepatitis B surface antigen by the same system in the presence of cadmium.
11. The vector of claim 1, said vector comprising all of said metallothionein gene, said gene sequence encoding hepatitis B surface antigen being inserted in said metallotionein gene between said promoter and the remainder of said metallothionein gene.
12. A mammalian cell tranformed with the vector of claim 1.
13. The mammalian cell of claim 12, said cell being a rodent fibroblast cell.
14. The cell of claim 13, said cell being a mouse C127 cell.
15. The cell of claim 13, said cell being an NIH 3T3 cell.
16. The vector of claim 1, said metallothionein gene being a mouse metallothionein gene.
17. A process for producing human hepatitis B
surface antigen comprising culturing the cell of claim 12 in culture medium and harvesting said human hepatitis B surface antigen from said culture medium.
surface antigen comprising culturing the cell of claim 12 in culture medium and harvesting said human hepatitis B surface antigen from said culture medium.
18. A cell exhibiting the characteristics of ATCC CRL 8399.
19. A plasmid exhibiting the characteristics of the transforming plasmid incorporated into cell ATCC
CRL 8399.
CRL 8399.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000476721A CA1272972A (en) | 1985-03-18 | 1985-03-18 | Vector encoding hepatitis b surface antigen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000476721A CA1272972A (en) | 1985-03-18 | 1985-03-18 | Vector encoding hepatitis b surface antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1272972A true CA1272972A (en) | 1990-08-21 |
Family
ID=4130045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000476721A Expired CA1272972A (en) | 1985-03-18 | 1985-03-18 | Vector encoding hepatitis b surface antigen |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1272972A (en) |
-
1985
- 1985-03-18 CA CA000476721A patent/CA1272972A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU558061B2 (en) | Processes for inserting dna into eucaryotic cells and for producing proteinaceous materials | |
| US5179017A (en) | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials | |
| US4634665A (en) | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials | |
| US4727028A (en) | Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof | |
| US4393133A (en) | Human hepatoma derived cell line, process for preparation thereof, and uses therefor | |
| JPH07106156B2 (en) | Manufacture of factor-VIII and related products | |
| Elder et al. | Simian virus 40 as a eukaryotic cloning vehicle | |
| HU208711B (en) | Method for preparing gm-csf and transformation vector containing csf/cdna, also a methold for purifying the csf protein | |
| JP2001186897A (en) | Method for producing protein by using homologous recombination | |
| JP2633227B2 (en) | Animal interferon | |
| Rao et al. | Premature chromosome condensation: a mechanism for the elimination of chromosomes in virus-fused cells | |
| Klessig et al. | Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell | |
| JP2525436B2 (en) | Protein production by cell culture | |
| WO1981002425A1 (en) | The use of eucaryotic promoter sequences in the production of proteinaceous materials | |
| Chang et al. | Transformation of human cultured fibroblasts with plasmids carrying dominant selection markers and immortalizing potential | |
| US4696898A (en) | Vector encoding hepatitis B surface antigen | |
| EP0517768A1 (en) | Mammalian expression vectors | |
| US6455275B1 (en) | DNA construct for producing proteinaceous materials in eucaryotic cells | |
| CA1272972A (en) | Vector encoding hepatitis b surface antigen | |
| JPH025862A (en) | Secretive gene manifestation indicator gene product | |
| JP3193999B2 (en) | An efficient method for identifiable expression of non-selective genes | |
| JPS6143121A (en) | Recombinant factor viii-r | |
| CA1309044C (en) | Method of producing foreign gene products | |
| Müller et al. | Cloning of mglB, the structural gene for the galactose-binding protein of Salmonella typhimurium and Escherichia coli | |
| WO1984000775A1 (en) | The use of eucaryotic promoter sequences in the production of proteinaceous materials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |